| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51f95273815aea14e23dffd10ffc2208 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A45D34-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D489-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-28 |
| filingDate |
2016-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd97314f5a0c654f2cb78ee8b54c67e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34ef783cf81f263af8d727b1e4e24b9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38964c7c27750d25de5da2c6cf51ab67 |
| publicationDate |
2017-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
FR-3040627-A3 |
| titleOfInvention |
PHARMACEUTICAL PRODUCT, METHOD FOR PRODUCING THE SAME, AND USE OF A PACKAGING FOR ITS STORAGE STABILIZATION |
| abstract |
The present invention relates to a packaged pharmaceutical comprising a pharmaceutical naloxone or pharmaceutically acceptable salt formulation thereof and a package; a process for the manufacture of a storage stable pharmaceutical comprising conditioning a pharmaceutical naloxone retardation formulation or a pharmaceutically acceptable salt thereof; the use of a packaging for storage stabilization of a pharmaceutical comprising a pharmaceutical naloxone retardation formulation or a pharmaceutically acceptable salt thereof; and the use of a package for decreasing the allylation of naloxone or its pharmaceutically acceptable salt during the storage of a pharmaceutical naloxone retardation formulation or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2015-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |